



Stabilis



Potassium chloride



Noms commerciaux

Cloreto de potassio	Portugal
Clorpotassium	Pérou
Clorura de potassiu	Roumanie
Cloruro de potasio	Argentine, Chili, Colombie, Espagne, Mexique, Vénézuéla
Kali Sterop	Belgique
Kaliolite	Mexique
Kalisteril	Finlande
Kaliumchlorid	Allemagne, Autriche, Danemark, Finlande, Hongrie, Islande, Pologne, Suède
Kasele	Mexique
Kasum	Pérou
Kelefusin	Mexique
Orakit	Argentine
Potassium Chloride	Arabie Saoudite, Canada, Egypte, Emirats Arabes Unis, Irlande, Malaisie
Potassium chlorure	France, Suisse, Tunisie
Potasyum Klorur	Turquie




























Stabilité en mélange

		50 mEq/l	25°C		Palonosetron hydrochloride : 25 µg/ml	4	
		5 & 20 mEq/l	25°C		Tirofiban : 25 µg/ml	4	
		2,9 mEq/l	25°C		Cisplatine : 0,1 mg/ml Magnesium sulfate : 1,9 mg/ml	28	
		0.04 mEq/l	25°C		Insulin glulisine : 1 U/ml	48	
		20 >> 80 mEq/l	25°C		Foscarnet sodium : 12 mg/ml	65	

















































Compatibilités

			
<input checked="" type="checkbox"/>	Potassium chloride : 1340 mEq/l Acetylsalicylic acid lysinate : 10 mg/ml		4698
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Aciclovir sodium : 5 mg/ml		336
<input checked="" type="checkbox"/>	Potassium chloride : 200 mEq/l Aldesleukin : 0.0338 MUI/ml		36
<input checked="" type="checkbox"/>	Potassium chloride : 100 mEq/l Allopurinol sodium : 3 mg/ml		307
<input checked="" type="checkbox"/>	Potassium chloride : 100 mEq/l Amifostine : 10 mg/ml		3
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Aminophylline : 25 mg/ml	RL	730
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Aminophylline : 25 mg/ml		730
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Amiodarone hydrochloride : 4 mg/ml		1036
<input checked="" type="checkbox"/>	Potassium chloride : 1340 mEq/l Amiodarone hydrochloride : 3 mg/ml		4698
<input checked="" type="checkbox"/>	Potassium chloride : 1 mEq/l Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml		4119
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Amiodarone hydrochloride : 1.8 mg/ml		242
	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Potassium chloride : 1 mEq/l Amiodarone hydrochloride : 12,5 mg/ml		4119
<input checked="" type="checkbox"/>	Potassium chloride : 100 mEq/l		1415
	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Potassium chloride : 1 mEq/l Amiodarone hydrochloride : 25 mg/ml		4119
<input checked="" type="checkbox"/>	Potassium chloride : 2 mEq/l	RL	4603
<input checked="" type="checkbox"/>	Potassium chloride : 2 mEq/l Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Potassium chloride : 100 mEq/l Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
<input checked="" type="checkbox"/>	Potassium chloride : 100 mEq/l		301
<input checked="" type="checkbox"/>	Potassium chloride : 2 mEq/l Ampicillin sodium : 100 mg/ml		4389
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Ampicillin sodium : 25 >> 135 mg/ml		730
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Ampicillin sodium : 25 >> 135 mg/ml	RL	730
<input checked="" type="checkbox"/>	Potassium chloride : 0.1 mEq/l Anidulafungin : 0.5 mg/ml		1982
<input checked="" type="checkbox"/>	Potassium chloride : 40 mEq/l Atropine sulfate : 0.5 mg/ml		1228
<input checked="" type="checkbox"/>	Potassium chloride : 400 mEq/l		939

	Potassium chloride : 40 mEq/l Atropine sulfate : 0.5 mg/ml	RL	1228
	Potassium chloride : 100 mEq/l Aztreonam : 40 mg/ml	◆	99
	Potassium chloride : 40 mEq/l Betamethasone sodium phosphate : 3 mg/ml	RL	1228
	Potassium chloride : 40 mEq/l Betamethasone sodium phosphate : 3 mg/ml	▲◆	1228
	Potassium chloride : 100 mEq/l Bivalirudin : 5 mg/ml	◆	1713
		▲	3976
	Potassium chloride : 200 mEq/l Caffeine : 10 mg/ml	∅	3964
	Potassium chloride : 40 mEq/l Calcium gluconate : 100 mg/ml	RL	730
	Potassium chloride : 100 mEq/l Caspofungin acetate : 0,7 mg/ml	▲	2247
	Potassium chloride : 40 mEq/l Caspofungin acetate : 0.5 mg/ml	▲	2233
	Potassium chloride : 40 mEq/l Cefalotin sodium : 200 mg/ml	RL	730
	Potassium chloride : 40 mEq/l Cefalotin sodium : 200 mg/ml	▲◆	730
	Potassium chloride Cefamandole nafate		1165
	Potassium chloride : 10 & 40 mEq/l Cefepime dihydrochloride : 4 mg/ml	▲◆	3548
	Potassium chloride : 0,00133 mEq/l Cefiderocol sulfate tosylate : 20 mg/mL	▲◆	4528
	Potassium chloride : 400 mEq/l Cefmetazole sodium : 100 mg/ml	💧	93
	Potassium chloride : 0,1 mEq/l Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Potassium chloride : 0,1 mEq/l Ceftaroline fosamil : 2,22 mg/ml	▲◆	3249
	Potassium chloride Ceftazidime		3883
	Potassium chloride : 100 mEq/l Ceftobiprole medocaril sodium : 2 mg/ml	▲◆	2269
	Potassium chloride : 100 mEq/l Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Potassium chloride : 100 mEq/l Ceftolozane / tazobactam : 10/5 mg/ml	▲◆	3828
	Potassium chloride : 10 & 40 mEq/l Cefuroxime sodium	▲	3687
	Potassium chloride : 40 mEq/l Chlorpromazine hydrochloride : 25 mg/ml	RL	1228
	Potassium chloride : 40 mEq/l Chlorpromazine hydrochloride : 25 mg/ml	▲◆	1228
	Potassium chloride : 1250 mEq/l Chlorpromazine hydrochloride : 0,26 mg/ml	◆	1289

	Potassium chloride : 20 & 80 mEq/l Cimetidine hydrochloride : 1.2 mg/ml		1201
	Potassium chloride : 40 mEq/l Ciprofloxacin lactate : 2 mg/ml		285
	Potassium chloride : 2000 mEq/l Ciprofloxacin lactate : 2 mg/ml		261
	Potassium chloride : 40 mEq/l Ciprofloxacin lactate : 2 mg/ml		289
	Potassium chloride : 40 mEq/l Ciprofloxacin lactate : 2 mg/ml		288
	Potassium chloride : 100 mEq/l Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Potassium chloride : 10 mEq/l Cisatracurium besylate : 5 mg/ml		3823
	Potassium chloride : 100 mEq/l Cladribine : 0.5 mg/ml		1496
	Potassium chloride : 100 mEq/l Cladribine : 0.015 mg/ml		1496
	Potassium chloride : 40 mEq/l Clonidine hydrochloride : 0,018 mg/ml		2018
	Potassium chloride : 1 mEq/l Clonidine hydrochloride : 0,018 mg/ml		2018
	Potassium chloride : 200 mEq/l Cloxacillin sodium : 100 mg/ml		3012
	Potassium chloride : 40 mEq/l Cyanocobalamine : 0.1 mg/ml		1228
	Potassium chloride : 40 mEq/l Cyanocobalamine : 0.1 mg/ml	RL	1228
	Potassium chloride Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
	Potassium chloride : 40 mEq/l Dexamethasone sodium phosphate : 4 mg/ml		730
	Potassium chloride : 40 mEq/l Dexamethasone sodium phosphate : 4 mg/ml	RL	730
	Potassium chloride : 100 mEq/l Dexmedetomidine : 4 µg/ml		1712
	Potassium chloride : 40 mEq/l Diazepam : 5 mg/ml	RL	730
	Potassium chloride : 40 mEq/l Diazepam : 5 mg/ml		730
	Potassium chloride : 40 mEq/l Digoxin : 250 µg/ml	RL	730
	Potassium chloride : 40 mEq/l Digoxin : 250 µg/ml		730
	Potassium chloride : 2000 mEq/l Diltiazem hydrochloride : 5 mg/ml		198
	Potassium chloride : 80 mEq/l Diltiazem hydrochloride : 1 & 5 mg/ml		198
	Potassium chloride : 2 mEq/l Dimenhydrinate : 10 mg/ml		4389
	Potassium chloride Dimenhydrinate		2087

		Potassium chloride : 40 mEq/l Diphenhydramine hydrochloride : 50 mg/ml	RL	1228
		Potassium chloride : 40 mEq/l Diphenhydramine hydrochloride : 50 mg/ml		1228
		Potassium chloride : 40 mEq/l Dobutamine hydrochloride : 2 mg/ml		1041
		Potassium chloride : 160 mEq/l Dobutamine hydrochloride : 1 mg/ml		1058
		Potassium chloride : 100 mEq/l Docetaxel : 0.9 mg/ml		1754
		Potassium chloride Dopamine hydrochloride : 0.8 mg/ml		738
		Potassium chloride : 40 mEq/l Dopamine hydrochloride : 40 mg/ml	RL	1228
		Potassium chloride : 40 mEq/l Dopamine hydrochloride : 40 mg/ml		1228
		Potassium chloride : 100 mEq/l Doripenem : 5 mg/ml		2262
		Potassium chloride : 100 mEq/l Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Potassium chloride : 40 mEq/l Droperidol : 1.25 mg/ml		1228
		Potassium chloride : 40 mEq/l Droperidol : 1.25 mg/ml	RL	1228
		Potassium chloride : 36 mEq/l Enalaprilate : 0,011 mg/ml		963
		Potassium chloride : 400 mEq/l Enalaprilate : 0.05 mg/ml		1315
		Potassium chloride : 40 mEq/l Epinephrine hydrochloride : 100 µg/ml		1228
		Potassium chloride : 40 mEq/l Epinephrine hydrochloride : 100 µg/ml	RL	1228
		Potassium chloride : 40 mEq/l Ergotamine tartrate : 0.5 mg/ml		1228
		Potassium chloride : 40 mEq/l Ergotamine tartrate : 0.5 mg/ml	RL	1228
		Potassium chloride : 40 mEq/l Ergotamine tartrate : 0.5 mg/ml		1228
		Potassium chloride : 0,4 mEq/l Esmolol hydrochloride : 10 mg/ml		384
		Potassium chloride : 40 mEq/l Ethacrynate sodium : 1 mg/ml	RL	730
		Potassium chloride : 40 mEq/l Ethacrynate sodium : 1 mg/ml		730
		Potassium chloride : 100 mEq/l Etoposide phosphate : 5 mg/ml		1410
		Potassium chloride : 13.4 mEq/l Famotidine : 2 mg/ml		215
		Potassium chloride : 40 mEq/l Famotidine : 0.2 mg/ml		398
		Potassium chloride : 100 mEq/l Fenoldopam mesylate : 80 µg/ml		1803

	Potassium chloride : 40 mEq/l Fentanyl citrate : 50 µg/ml		1228
	Potassium chloride : 40 mEq/l Fentanyl citrate : 50 µg/ml	RL	1228
	Potassium chloride : 100 mEq/l Filgrastim : 30 µg/ml		244
	Potassium chloride : 40 mEq/l Flucloxacillin sodium : 20 mg/ml		1232
	Potassium chloride : 100 mEq/l Fludarabine phosphate : 1 mg/ml		492
	Potassium chloride : 40 mEq/l Fluorouracil : 50 mg/ml	RL	1228
	Potassium chloride : 40 mEq/l Fluorouracil : 50 mg/ml		1228
	Potassium chloride : 100 mEq/l Fosfomycin : 30 mg/ml		4055
	Potassium chloride : 40 mEq/l Furosemide : 10 mg/ml	RL	1228
	Potassium chloride : 40 mEq/l Furosemide : 1 mg/ml		1232
	Potassium chloride : 1250 mEq/l Furosemide : 5,21 mg/ml		1289
	Potassium chloride : 40 mEq/l Furosemide : 10 mg/ml		1228
	Potassium chloride : 300 mEq/l Gallium nitrate : 1 mg/ml		91
	Potassium chloride : 100 mEq/l Gemcitabine hydrochloride : 10 mg/ml		1423
	Potassium chloride : 20 mEq/l Gentamicin sulfate : 30 mg/ml		2335
	Potassium chloride : 40 mEq/l Granisetron hydrochloride : 1 mg/ml		57
	Potassium chloride : 10 mEq/l Heparin sodium : 500 UI/ml		3823
	Potassium chloride : 1250 mEq/l Heparin sodium : 58,34 UI/ml		1289
	Potassium chloride : 200 mEq/l Heparin sodium : 50 UI/ml	∅	317
	Potassium chloride : 100 mEq/l Hetastarch : 60 mg/ml		1721
	Potassium chloride : 40 mEq/l Hydralazine hydrochloride : 20 mg/ml		1228
	Potassium chloride : 40 mEq/l Hydralazine hydrochloride : 20 mg/ml	RL	1228
	Potassium chloride : 500 & 1000 mEq/l Hydromorphone hydrochloride : 5 >> 20 mg/ml		66
	Potassium chloride : 1000 mEq/l Hydromorphone hydrochloride : 25 mg/ml		66
	Potassium chloride : 2 mEq/l Ibuprofen lysinate : 10 mg/ml		4419
	Potassium chloride : 30 mEq/l Idarubicin hydrochloride : 1 mg/ml		491

	Potassium chloride : 200 mEq/l Indomethacin sodium trihydrate : 1 mg/ml		467	
	Potassium chloride : 40 mEq/l Insulin : 40 UI/ml	RL	730	
	Potassium chloride : 40 mEq/l Insulin : 40 UI/ml		730	
	Potassium chloride : 1 & 2 mEq/l Insulin aspart : 1 UI/ml		1508	
	Potassium chloride : 100 mEq/l Isavuconazonium sulfate : 1.5 mg/ml		3829	
	Potassium chloride : 40 mEq/l Isoprenaline hydrochloride : 0.2 mg/ml		1228	
	Potassium chloride : 40 mEq/l Isoprenaline hydrochloride : 0.2 mg/ml	RL	1228	
	Potassium chloride : 40 mEq/l Kanamycin sulfate : 250 mg/ml		730	
	Potassium chloride : 40 mEq/l Kanamycin sulfate : 250 mg/ml	RL	730	
	Potassium chloride : 2000 mEq/l Ketamine hydrochloride : 50 mg/ml		2109	
	Potassium chloride : 400 mEq/l Labetalol hydrochloride : 1 mg/ml		386	
		Potassium chloride : 100 mEq/l Lansoprazole : 0.55 mg/ml		1625
	Potassium chloride : 40 mEq/l Levofloxacin : 5 mg/ml	∅	2335	
	Potassium chloride : 40 mEq/l Lidocaine hydrochloride : 20 mg/ml		730	
	Potassium chloride : 40 mEq/l Lidocaine hydrochloride : 20 mg/ml	RL	730	
	Potassium chloride : 100 mEq/l Linezolid : 2 mg/ml	∅	1925	
	Potassium chloride : 1000 mEq/l Lorazepam : 0.33 mg/ml		186	
	Potassium chloride : 40 mEq/l Magnesium sulfate : 100 mg/ml	RL	1228	
	Potassium chloride : 40 mEq/l Magnesium sulfate : 100 mg/ml		1228	
	Potassium chloride : 10000 & 40000 mEq/l Mannitol : 20 mg/ml		1906	
	Potassium chloride : 100 mEq/l Melfalan : 0.1 mg/ml		169	
	Potassium chloride : 2000 mEq/l Meropenem : 50 mg/ml		4319	
		Potassium chloride : 40 mEq/l Methylprednisolone sodium succinate : 40 mg/ml		730
		Potassium chloride : 40 mEq/l Methylprednisolone sodium succinate : 40 mg/ml	RL	730
	Potassium chloride : 100 mEq/l Micafungin : 1.5 mg/ml		2108	
	Potassium chloride : 1000 mEq/l Midazolam hydrochloride : 5 mg/ml	∅	186	

	Potassium chloride : 10 mEq/l Midazolam hydrochloride : 2.1 mg/ml		3823
	Potassium chloride : 2000 mEq/l Milrinone lactate : 0.8 mg/ml		813
	Potassium chloride : 40 mEq/l Minocycline hydrochloride : 50 mg/ml	RL	1228
	Potassium chloride : 40 mEq/l Minocycline hydrochloride : 50 mg/ml		1228
	Potassium chloride : 40 mEq/l Morphine hydrochloride : 15 mg/ml		1228
	Potassium chloride : 40 mEq/l Morphine hydrochloride : 15 mg/ml	RL	1228
	Potassium chloride : 200 mEq/l N-acetylcysteine : 200 mg/ml	∅	3766
	Potassium chloride : 200 mEq/l Naloxone hydrochloride : 0.4 mg/ml	∅	3408
	Potassium chloride : 40 mEq/l Neostigmine methylsulfate : 0.5 mg/ml	RL	1228
	Potassium chloride : 40 mEq/l Neostigmine methylsulfate : 0.5 mg/ml		1228
	Potassium chloride Netilmicin sulfate : 3 mg/ml		1200
	Potassium chloride : 400 mEq/l Nicardipine hydrochloride : 0.1 mg/ml		1490
	Potassium chloride : 40 mEq/l Nicardipine hydrochloride : 0.05 & 0.5 mg/ml		44
	Potassium chloride : 10 mEq/l Nitroglycerin : 0.2 mg/ml		3823
	Potassium chloride : 100 mEq/l Ondansetron hydrochloride : 1 mg/ml		334
	Potassium chloride : 0.2 mEq/l Oritavancin : 0.8 >>2 mg/ml		3152
	Potassium chloride : 40 mEq/l Oxacillin sodium : 100 mg/ml	RL	1228
	Potassium chloride : 40 mEq/l Oxacillin sodium : 100 mg/ml		1228
	Potassium chloride : 100 mEq/l Oxaliplatin : 0,5 mg/ml		1662
	Potassium chloride Oxaliplatin		3634
	Potassium chloride : 40 mEq/l Oxytocin : 600 UI/ml	RL	1228
	Potassium chloride : 40 mEq/l Oxytocin : 600 UI/ml		1228
	Potassium chloride : 100 mEq/l Paclitaxel : 1.2 mg/ml		248
	Potassium chloride : 100 mEq/l Palonosetron hydrochloride : 50 µg/ml		2279
	Potassium chloride : 20 >> 4000 mEq/l Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
	Potassium chloride Pantoprazole sodium		2090

		Potassium chloride : 3 mEq/l Paracetamol : 10 mg/ml		4742
		Potassium chloride : 100 mEq/l Pemetrexed disodium : 20 mg/ml		1953
		Potassium chloride : 40 mEq/l Penicillin G potassium	RL	730
		Potassium chloride : 40 mEq/l Penicillin G potassium		730
		Potassium chloride : 400 mEq/l Pethidine hydrochloride : 10 mg/ml		62
		Potassium chloride : 40 mEq/l Phenytoin sodium : 50 mg/ml		730
		Potassium chloride : 40 mEq/l Phenytoin sodium : 50 mg/ml	RL	730
		Potassium chloride : 100 mEq/l Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Potassium chloride : 100 mEq/l Plazomicin sulfate : 24 mg/ml		4145
		Potassium chloride : 1341 mEq/l Posaconazole : 1,2 mg/ml		4521
		Potassium chloride Posaconazole		4380
		Potassium chloride : 40 mEq/l Procainamide hydrochloride : 100 mg/ml	RL	1228
		Potassium chloride : 40 mEq/l Procainamide hydrochloride : 100 mg/ml		1228
		Potassium chloride : 40 mEq/l Prochlorperazine edysilate : 5 mg/ml		1228
		Potassium chloride : 40 mEq/l Prochlorperazine edysilate : 5 mg/ml	RL	1228
		Potassium chloride : 40 mEq/l Promethazine hydrochloride : 50 mg/ml		1228
		Potassium chloride : 40 mEq/l Promethazine hydrochloride : 50 mg/ml	RL	1228
		Potassium chloride : 500 & 4000 mEq/l Propafenone hydrochloride : 1 mg/ml		925
		Potassium chloride : 200 mEq/l Propofol		660
		Potassium chloride : 100 mEq/l Propofol : 10 mg/ml		300
		Potassium chloride : 40 mEq/l Propranolol hydrochloride : 1 mg/ml		1228
		Potassium chloride : 40 mEq/l Propranolol hydrochloride : 1 mg/ml	RL	1228
		Potassium chloride : 40 mEq/l Quinupristine/dalfopristine : 2 mg/ml		1513
		Potassium chloride : 10 & 60 mEq/l Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Potassium chloride : 1000 mEq/l Remifentanil hydrochloride : 120 µg/ml		3176
		Potassium chloride : 100 mEq/l Remifentanil hydrochloride : 25 & 250 µg/ml		59

		Potassium chloride : 200 mEq/l Salbutamol sulfate : 1 mg/ml	∅	3216
		Potassium chloride : 100 mEq/l Sargramostim : 10 µg/ml	▲	335
		Potassium chloride : 40 mEq/l Scopolamine hydrobromide : 0.86 mg/ml	RL	1228
		Potassium chloride : 40 mEq/l Scopolamine hydrobromide : 0.86 mg/ml	▲◆	1228
		Potassium chloride : 40 mEq/l Sodium bicarbonate : 75 mg/ml	RL	730
		Potassium chloride : 40 mEq/l Sodium bicarbonate : 75 mg/ml	▲◆	730
		Potassium chloride : 10 mEq/l Sodium bicarbonate : 84 mg/ml	▲	3823
		Potassium chloride : 0,1 mEq/l Sulbactam/durlobactam : 15/15 mg/ml	▲	4801
		Potassium chloride : 2000 mEq/l Tacrolimus : 1000 µg/ml	▲	479
		Potassium chloride : 100 mEq/l Tedizolid phosphate : 0.8 mg/ml	▲	3827
		Potassium chloride : 100 mEq/l Telavancin hydrochloride : 7.5 mg/ml	▲◆	3254
		Potassium chloride : 100 mEq/l Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Potassium chloride : 100 mEq/l Teniposide : 0.1 mg/ml	◆	905
		Potassium chloride : 200 mEq/l Theophylline : 4 mg/ml	∅	317
		Potassium chloride Thiopental sodium : 25 mg/ml	▲	3767
		Potassium chloride : 100 mEq/l Thiotepa : 1 mg/ml	◆	249
		Potassium chloride Tigecycline	▲	3332
		Potassium chloride : 10 & 40 mEq/l Tirofiban : 50 µg/ml	▲◆	1420
		Potassium chloride Tirofiban		1512
		Potassium chloride : 80 mEq/l Verapamil hydrochloride : 0.08 mg/ml	▲◆	1057
		Potassium chloride : 100 mEq/l Vinorelbine tartrate : 1 mg/ml	▲	84
		Potassium chloride : 40 mEq/l Warfarin sodium : 2 mg/ml	◆	315
		Potassium chloride : 670 mEq/l Zidovudine : 4 mg/ml	◆	337



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
44	Revue	Baaske DM, DeMay JF, Latona CA, Mirmira S, Sigvardson KW. Stability of nicardipine hydrochloride in intravenous solutions. Am J Health-Syst Pharm 1996 ; 53: 1701-1705.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
66	Revue	Avelar MA, Walker SE. Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin. Can J Hosp Pharm 1996 ; 49: 140-145.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
214	Revue	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
242	Revue	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
246	Revue	McDonald C, Boddy M, Garas G. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm 1996 ; 26: 560-561.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
261	Revue	Percy LA, Rho JP. Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 715-716.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
467	Revue	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.

660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
730	Revue	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
738	Revue	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
925	Revue	Dupuis LL, Trope A, Giesbrecht E, Wong B. Compatibility and stability of propafenone hydrochloride with five critical-care medications. Can J Hosp Pharm 1998 ; 51: 55-57.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
963	Revue	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1036	Revue	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1165	Revue	Bowtle WJ, Heasman MJ, Prince AP, Easthope DA. Compatibility of the cephalosporin, cefamandole nafate with injections. Int J Pharm 1980 ; 4: 263-265.
1200	Revue	Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.

1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1289	Revue	Hecq JD, Evrard JM, Gillet P, Grosdent N. Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l'héparine sodique en perfusion continue. Pharmakon 1998 ; 116: 145-148.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1420	Revue	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1513	Laboratoire	Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit Monarch Pharmaceuticals Ireland 2006
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.

1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1906	Revue	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.

2279	Revue	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3176	Poster	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3183	Revue	Sewell G Physical and chemical stability of cisplatin infusions in PVC containers. EJOP 2010 ; 4, 3: 11-13.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3548	Laboratoire	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007
3634	Laboratoire	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3687	Laboratoire	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Revue	Juan E.P, Palau M.M, Cerdá S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.

3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidone/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3935	Laboratoire	Insuline glulisine (Insulines Sanofi Apidra®) - Résumé des caractéristiques du produit Sanofi Laboratoire 2016
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119	Poster	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Revue	Holt R.J, Siebert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4521	Revue	Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4698	Revue	Ayari G, Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	électrolyte		Injectable
	Noms commerciaux		Stabilité en mélange
	Contenant		Solvant
	Concentration		Température
	Conservation		Molécule
	Durée de stabilité		Bibliographie
	Verre		Glucose 5%
	Lumière		Heure
	Polyvinyl chlorure		NaCl 0,9% ou glucose 5%
	Chlorure de sodium 0,9%		A l'abri de la lumière
	Jour		Polyoléfine
	Non précisée		Non précisé
	Compatibilités		Compatible
RL	Ringer lactate		Turbidité immédiate
	Incompatible		Nutrition parentérale (mélange ternaire)
	Précipitation immédiate		Nutrition parentérale (mélange binaire)
	Aucun		Eau pour préparation injectable
	NaCl 0,9% + bactériostatique		Précipitation en 1 heure
	Changement de couleur en 24 heures		Précipitation en 4 heures
	NaCl 0,45% Glucose 5%		Solvant spécifique
	Incompatibilité non précisée		Instabilité de l'émulsion à 12 heures
	Voie d'administration		Perfusion intraveineuse
	Bibliographie		Dictionnaire